What this trial means for you
This study is recruiting now at 1 US site. It's studying see the official record for endometrial cancer survivors, weight management, early stage endometrial cancer.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
This study is being done to understand how oncologists can engage a multidisciplinary team to help endometrial cancer survivors with obesity to engage in a weight management program and potentially start a weight loss medication. Obesity often impacts the future health and longevity of early-stage endometrial cancer survivors more than their cancer diagnosis. Patients will be referred to the KUMC OB/Gyn weight management clinic to discuss weight management options. * If patients decide to use medications for weight loss, then the study will collect data from their chart that is recorded as part of routine monitoring for patients on weight loss medications. * If patients decide not to use any medications, the study will monitor physical exam and lab data collected as part of their routine medical care. The study will also try to understand reasons why patients did or did not start using a weight loss medication.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * ≥18 years old * ECOG 0-2 * BMI ≥ 30kg/m2 * Completed surgical staging with no evidence of residual disease * Endometrioid endometrial adenocarcinoma, p53 wild type * Stage 1 * Undergoing active surveillance +/- brachytherapy Exclusion Criteria: * Unable to participate in behavior weight loss * Stroke, heart attack, end stage liver disease, or end stage kidney disease during the last 6 months. * Currently on a GLP-1 agonist * Currently on insulin
Study sites by state
Kansas
- University of Kansas Medical Center — Kansas City · Recruiting now
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)